Oncology Central

Inflammatory, insulin resistance metabolic markers and pancreatic cancer: quo vadis?


Pancreatic cancer is an aggressive and often fatal malignancy with an overall mortality to incidence ratio of 0.98. In 2012, 338,000 new cases were diagnosed worldwide and 330,000 deaths were recorded [1]. In the USA, pancreatic cancer is currently the fourth leading cause of cancer death, but it is projected to become the second leading cause before 2020 [2]. The 5-year survival rate (<5%) is lower than that of all other major cancers. Standard treatment is cytotoxic chemotherapy, which can be effective, but disease progression generally ensues within 6–12 months.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.